AGC Biologics Adds Cell Therapy Suites to Longmont Plant

Published on: 

Expansion allows facility to provide E2E services in one location, including commercial manufacturing.

AGC Biologics, a contract development and manufacturing organization (CDMO), has added three new Grade B cell therapy suites to its Longmont, CO facility. The new addition provides two new process suites and one new flex suite, bringing expanded capabilities to the facility. With more than 30,000 square feet of added space, the new multiproduct suites feature modular clean room design, flexible capacity configuration, and cell therapy equipment for open and closed processes, offering autologous and allogeneic cell therapy manufacturing.


The expansion allows the location to offer end-to-end (E2E) cell therapy development and manufacturing services in one location. The new labs extend the capabilities at the site and complement the site’s viral vector development and manufacturing services; developers now have one centralized location that can offer a full set of services for bringing their products to market. Other key features of this site include support for early-stage process development services, commercial manufacturing, quality control and analytics, fill-finish capabilities, and an onsite warehouse.

“The new cell therapy suites are a tremendous achievement for this site,” says Whitney Sandberg, general manager, AGC Biologics Colorado. “ … This is the final piece for this campus that accompanies our comprehensive viral vector capabilities and gives developers a true end-to-end manufacturing site in North America to support their product’s every need, at any stage.”